Global Biopharmaceuticals Market
Biopharmaceuticals Global Business Report 2024 with Focus on 200+ Select Players Including Abbott, Amgen, Biogen, Eli Lilly and Co, F. Hoffmann-La Roche, J&J, Merck, Novo Nordisk, Pfizer, Sanofi
23 août 2024 07h20 HE | Research and Markets
Dublin, Aug. 23, 2024 (GLOBE NEWSWIRE) -- The "Biopharmaceuticals - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for...
22157.jpg
Cancer Engineered Antibody Therapeutics Market Analysis 2024: Technology Advances and Increasing Interest from Tier I Pharmaceuticals Driving Growth of Engineered Antibodies
15 août 2024 07h35 HE | Research and Markets
Dublin, Aug. 15, 2024 (GLOBE NEWSWIRE) -- The "Engineered Antibody Therapeutics for Cancer" report has been added to ResearchAndMarkets.com's offering.This study analyzes the emergence of...
Dyadic Logo Current.jpg
Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
13 août 2024 16h05 HE | Dyadic International, Inc.
Alternative Proteins Entered into a development and commercialization partnership for the sale of animal-free recombinant albumin products with Proliant Health and BiologicalsEntered into a joint...
22157.jpg
Anti TIGIT Antibodies Clinical Trials Market Outlook to 2028: Insight on 50+ Anti TIGIT Antibodies in Clinical Trials
09 août 2024 05h22 HE | Research and Markets
Dublin, Aug. 09, 2024 (GLOBE NEWSWIRE) -- The "Anti TIGIT Antibodies Clinical Trials & Market Opportunity Outlook 2028" report has been added to ResearchAndMarkets.com's offering. Anti TIGIT...
22157.jpg
Trispecific Antibodies Clinical Trials & Market Outlook Report 2024: Innovative Trispecific Antibody Therapy - A New Frontier in Cancer and Disease Treatment
09 août 2024 04h19 HE | Research and Markets
Dublin, Aug. 09, 2024 (GLOBE NEWSWIRE) -- The "Global Trispecific Antibodies Clinical Trials & Market Outlook 2024" report has been added to ResearchAndMarkets.com's offering.The blueprint in...
22157.jpg
Multispecific Antibodies Market Research, Drug Sales, Price & Clinical Trials Insights 2023-2029: 13 Approved, 900 Multispecific Antibodies in Clinical Trials by Company, Country, Indication, & Phase
09 août 2024 04h16 HE | Research and Markets
Dublin, Aug. 09, 2024 (GLOBE NEWSWIRE) -- The "Global Multispecific Antibodies Market, Drug Sales, Price & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's...
Global Research Antibodies Market
Research Antibodies Market Research - Global Forecasts from 2024 to 2029: Expanding Requirement for Personalised Medication and Structure-based Medication Plans to Bolster Growth
24 juin 2024 10h17 HE | Research and Markets
Dublin, June 24, 2024 (GLOBE NEWSWIRE) -- The "Global Research Antibodies Market - Forecasts from 2024 to 2029" report has been added to ResearchAndMarkets.com's offering.The global research...
22157.jpg
$1.9 Billion Biopharmaceuticals Manufacturing Consumables Testing Market Report, 2034: Global and Regional Data Projections by Type, Raw Material, Application, and End-user
13 juin 2024 05h16 HE | Research and Markets
Dublin, June 13, 2024 (GLOBE NEWSWIRE) -- The "Global Biopharmaceuticals Manufacturing Consumables Testing Market" report has been added to ResearchAndMarkets.com's offering.The global...
Global Monoclonal Antibodies Market
Global Monoclonal Antibodies Market Report 2024-2032, by Production Method, Source, Indication, End Use and Region
12 juin 2024 11h25 HE | Research and Markets
Dublin, June 12, 2024 (GLOBE NEWSWIRE) -- The "Global Monoclonal Antibodies Market Report by Production Method, Source, Indication, End Use, and Region 2024-2032" report has been added to ...
22157.jpg
Trispecific Antibodies Set to Transform the Future of Immunotherapy: Trispecific Antibodies Clinical Trials Insight by Company, Country, Indication & Phase
07 juin 2024 02h59 HE | Research and Markets
Dublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Global Trispecific Antibodies Clinical Trials & Market Outlook 2024" report has been added to ResearchAndMarkets.com's offering. The blueprint...